These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments.   

investors@repligen.com

  • Repligen is listed on NASDAQ Global Markets under the ticker RGEN.
  • Repligen began trading on the NASDAQ May 6, 1986 under the ticker RGEN.
  • If you hold your shares in a brokerage account, please contact your broker.
    If you hold your stock certificates directly, please contact our transfer agent, American Stock Transfer & Trust Company with your question or to provide your new contact information.

    American Stock Transfer & Trust Company
    59 Maiden Lane
    Plaza Level
    New York, NY 10038
    Phone: 877.777.0800, select option 1
    Web: www.amstock.com
  • No, Repligen does not have a direct purchase program. You may purchase stock through a brokerage.
  • Repligen has not historically paid cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future. We are focused on building value for shareholders through reinvestment in programs and products aimed at delivering sustainable profitability and optimizing earnings margins.
  • As of January 1, 2012, our fiscal year ends on December 31 of each calendar year. Previously, the Company's fiscal year ended on March 31 of each year.
  • As of our record date of April 7, 2015, the Company had 32,851,000 shares of common stock outstanding.
  • Ernst & Young, LLP.
  • Repligen was incorporated in May 1981 in Delaware.
  • Repligen’s principle executive offices are located in Waltham, Massachusetts. We have additional manufacturing facilities in Lund, Sweden.
Copyright 2016, © SNL Financial LC  Terms of Use